Agendia's MammaPrint(R) Micro-Array Test Confirmed to Be a Reliable Diagnostic Tool for Breast Cancer
Posted on: Wednesday, 8 November 2006, 03:00 CST
In a publication entitled 'Converting a breast cancer microarray signature into a high-throughput diagnostic test' in the international journal BMC Genomics, made available online on October 31 2006, it is shown that micro-array technology can be a reliable tool for use in a clinical diagnostic setting.
In 2002 a 70-gene tumor expression profile was established as a powerful predictor of disease outcome in breast cancer patients. To facilitate its use in a diagnostic setting, the 70-gene prognosis profile was translated into a customized micro-array named MammaPrint(R) containing a reduced set of 1,900 probes suitable for high throughput processing. In the present publication, it is clearly demonstrated that micro-array technology can be used as a reliable diagnostic tool. The data demonstrate the reproducibility and robustness of the custom-made micro-array. The array is therefore an excellent tool to predict outcome of disease in breast cancer patients.
Dr. Laura van 't Veer, Chief Operating Officer at Agendia comments: 'Using the MammaPrint(R) micro-array test in the clinical setting will provide more accurate information on recurrence risk as compared to conventional clinical criteria and will thus improve the guidance for the requirement of adjuvant therapy for women diagnosed with breast cancer. As a direct result, many patients could be potentially spared the side effects and risks of such treatment, improving quality of life and reducing healthcare costs'.
About Agendia
Agendia is a world leader in gene expression analysis-based diagnostics. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first to commercialize a prognostic test - MammaPrint(R) - that predicts the chance of breast cancer recurrence. CupPrint(R)*, the second product in the market of Agendia, is used for the identification of Cancers of Unknown Primary. Agendia maintains close ties with NKI/AVL, ensuring access to the latest developments in cancer research. Apart from the development of new cancer diagnostics, Agendia offers its expertise in finding new predictive gene expression profiles to companies focusing on new drug development in the area of oncology.
*CupPrint is based on a license to the TUO database of AviaraDx.
More information about Agendia BV is available at www.agendia.com
CONTACT INFORMATION: Agendia: Laura van't Veer COO of Agendia +31-20-5129161 Contact via http://www.marketwire.com/mw/emailprcntct?id=F30138DF0934D4EA
SOURCE: Agendia BV
Source: MARKET WIRE
Related Articles
- Medicare Cuts Will Force Many Cancer Centers To Close, Stop Seeing Medicare Patients, Lay Off Staff, According To ASTRO Survey
- Gene Signature Could Predict Patient Response To Therapy For Gastrointestinal Stromal Tumors
- James L. Wittliff, Ph.D., FACB, to Present 'Predicting Breast Cancer Outcome With Gene Expression Signatures on the Ziplex(R) System' at the Association for Molecular Pathology Conference, October 30
- Webcast On CombiMatrix's Comprehensive Cancer Array Available On Website
- Epigenomics Licenses Septin 9 Colorectal Cancer Biomarker to Quest Diagnostics
- University Hospitals Researchers Initiate Gene Therapy Trial in Patients With Advanced Skin Cancer
- FDA Provides Positive Opinion on the Regulatory Status of CombiMatrix's First Array-Based Molecular Diagnostic
- Saint Agnes to Open $1.3m Diagnostic Breast Center By Fall
- Avon Foundation Presents Grant to MUSC Hollings Cancer Center to Enhance Comprehensive Breast Cancer Program
- Kosan Reports KOS-862 Interim Phase II Results in Patients With Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium
 |
 |
User Comments (0)
RSS Feeds